Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections

Patient preference information (PPI) is a way to incorporate the patient voice in the evaluation of medical devices. The US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has been working to encourage the voluntary inclusion of PPI throughout the medical device lifecycle for nearly a decade. This article reflects CDRH's efforts to encourage collection of PPI and offers perspectives on the future of PPI in the evaluation of medical devices. CDRH regulatory guidance, public meetings, and collaborations relating to PPI were explored. Since 2012 when CDRH issued guidance on how PPI can be used as scientific evidence in the benefit-risk regulatory submission, CDRH has issued 5 subsequent guidance documents expanding on the use of PPI in medical device evaluations. CDRH remains committed to advancing the science and application of PPI in the medical device ecosystem through many collaborations with professional organizations, patient advocacy groups, and academic institutions. By hosting and actively participating in multiple scientific and regulatory public meetings and conferences, CDRH fosters a continuous learning environment where the experience of using PPI in regulatory submissions can be shared. A September 2020 meeting cosponsored by FDA and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) discussed the state of PPI in regulatory applications and beyond. This article describes these pivotal events that have helped to increase the use of PPI in medical device evaluation as well as discusses future applications of PPI. •The US Food and Drug Administration Center for Devices and Radiological Health (CDRH) encourages the voluntary inclusion of patient preference information (PPI), where appropriate, to evaluate medical devices.•In addition to recommendations presented in guidance documents, CDRH works to advance the science and application of PPI in the medical device ecosystem through many collaborations with professional organizations, patient advocacy groups, public–private partnerships, and academic institutions.•The application of PPI in medical device evaluation has evolved over the past decade and continues to evolve with new opportunities to apply PPI to preference-sensitive areas, emerging technologies, breakthrough devices, and registries.